Fairfax Health Center Clinic/Center - Federally Qualified Health Center (FQHC) Medicare: Medicare Enrolled Practice Location: 1199 Main St, Fairfax, VT 05454 Phone: 802-849-2844 |
Northwestern Medical Center/georgia Health Care Clinic/Center Medicare: Not Enrolled in Medicare Practice Location: 4178 Highbridge Rd, Fairfax, VT 05454 Phone: 802-752-1930 Fax: 802-524-2867 |
Georgia Health Center Clinic/Center - Federally Qualified Health Center (FQHC) Medicare: Medicare Enrolled Practice Location: 4178 Highbridge Rd, Fairfax, VT 05454 Phone: 802-255-5500 |
Audrey Von Lepel Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1199 Main St, Fairfax, VT 05454 Phone: 802-849-2844 Fax: 802-849-2644 |
Fairfax Associates In Medicine Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1199 Main St, Fairfax, VT 05454 Phone: 802-849-2844 Fax: 802-849-2644 |
Fairfax Associates In Medicine Pllc Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1199 Main St, Fairfax, VT 05454 Phone: 802-849-2844 Fax: 802-849-2644 |
News Archive
A Leon County circuit judge today blocked a proposed [state] constitutional amendment that targets the federal health-reform law, saying Florida Republican lawmakers included wording in the proposal that would mislead voters. Judge James O. Shelfer said the proposal -- dubbed by lawmakers as the 'Health Care Freedom' amendment -- should not go on the November ballot. He described wording in a ballot summary as 'manifestly misleading.'
Kaiser Health News reports that "Senate Finance Committee Chairman Max Baucus today unveiled a health care bill that would require most individuals to have health insurance.
Women who lived in villages sprayed with DDT to reduce malaria gave birth to 33 per cent more baby boys with urogenital birth defects (UGBD) between 2004 and 2006 than women in unsprayed villages, according to research published online by the UK-based urology journal BJUI.
Lumena Pharmaceuticals, a company developing oral therapeutics for rare liver diseases, today announced the initiation of a global clinical program to evaluate its drug candidate LUM001 in children with Alagille syndrome. The first patient has been dosed in the IMAGO Phase II study being conducted in the U.K., and enrollment of pediatric patients is expected to begin later this year in the ITCH Phase II study in the U.S.
BioGaia has signed four different distribution agreements for the exclusive rights to sell its oral health products.
› Verified 7 days ago